Ask VialBase
Enforcement action · FDA, DOJ, HHS, state boards

FDA Crackdown on Peptide Vendors (2025-2026) — VialBase News

Last updated · June 13, 2026

The FDA Crackdown on Peptide Vendors (2025-2026)

The “FDA crackdown” is the sustained 2024-2026 wave of federal and state action that ended the grey-market and compounded-peptide boom. It is not a single rule or raid — it is the convergence of three forces: (1) drug-shortage resolution that switched off the legal basis for compounding GLP-1s, (2) the 503A/503B bulk-substance framework that keeps most research peptides off-limits to compounding, and (3) escalating enforcement — mass FDA warning letters, DOJ criminal prosecutions, and state board actions — that pushed vendors to shut down. This note is the canonical hub; each phase links to its dated detail note.

The crackdown is what closed Science-Bio (Jan 2026) and Peptide-Sciences (Mar 2026) and triggered the warning letters that named Prime-Sciences, Mile-High-Compounds, and Gram-Peptides. It is the same wave that produced the Amino-Asylum raid.

Important nuance for VialBase content: the crackdown targets vendors and marketing claims, not personal possession. Most research peptides remain legal to possess and to sell labeled “for research use only / not for human consumption” — but the FDA judges intended use by marketing context, not by the disclaimer, so the grey-market disclaimer is legal cover, not a safe harbor.

Two distinct regulatory tracks (don’t conflate them)

The crackdown runs on two parallel tracks that get muddled in vendor marketing:

  1. The GLP-1 track (semaglutide / tirzepatide / liraglutide). These are FDA-approved drugs. Compounding was only ever legal because of a declared shortage. When the shortage resolved, the legal basis evaporated. This track is essentially closed.
  2. The research-peptide track (BPC-157, TB-500, CJC-1295, etc.). These are unapproved drugs. They were never legally compoundable for human use once placed in Category 2, and they remain unapproved even as the FDA re-evaluates them in 2026.

See FDA-503A-Category-System for the framework underneath both tracks.

Timeline

For the full chronology see regulatory-timeline-2024-2026. Key inflection points:

2023-2024 — The framework tightens

Jan-Feb 2025 — Shortage resolution + end of the category pipeline

  • Jan 7, 2025: FDA finalizes its revised interim policy on compounding from bulk drug substances — no new substances enter the Category 1/2/3 pipeline; new nominations must complete full PCAC review first (Federal Register, 2025-01-07).
  • Feb 21, 2025: FDA issues a Declaratory Order finding the semaglutide shortage resolved, removing all presentations from the shortage list (Foley & Lardner; McDermott).
  • Feb 24, 2025: Outsourcing Facilities Association (OFA) sues FDA over the semaglutide determination — OFA v. FDA, 4:25-cv-00174 (N.D. Tex.) (Cardiovascular Business). See GLP1-Manufacturer-Litigation-2025.

Mar-May 2025 — Compounding discretion sunsets, litigation fails

  • Compounding enforcement-discretion deadlines (the sunset):
    • Tirzepatide: 503A ended Feb 18, 2025, 503B ended Mar 19, 2025 (NCPA).
    • Semaglutide: 503A ended Apr 22, 2025, 503B ended May 22, 2025 (Alston & Bird).
  • Apr 24, 2025: Court denies OFA’s preliminary injunction in the semaglutide case; the enforcement timelines hold (FDA compounder-policy statement, 4/28/2025 update). A parallel OFA challenge on tirzepatide was likewise denied. After these deadlines, neither tirzepatide nor semaglutide appears on the 503B bulks list or the shortage list — so compounding them from bulk is no longer lawful (FDA, same source).
  • Apr 2025: Eli Lilly sues Strive and Empower over compounded tirzepatide; FDA warning letter to Empower’s Texas facility. See GLP1-Manufacturer-Litigation-2025.

Jun-Oct 2025 — Enforcement escalates from letters to raids and indictments

  • Jun 2025: FDA/DOJ raid on Amino-Asylum, a high-volume research-peptide vendor — physical enforcement, not just paperwork. See Amino-Asylum-FDA-Raid-Jun-2025.
  • Sep 9, 2025: FDA/HHS announce a broad initiative against misleading direct-to-consumer pharma advertising (thousands of letters; ~100 cease-and-desist) — the policy umbrella for the peptide letters (STAT, 2025-09-19).
  • Sep 16, 2025: FDA publishes 55+ warning letters to online sellers of compounded GLP-1s — the largest single-day enforcement action against the compounding industry (Wilson Sonsini). Cited violations: “sameness” claims equating compounded product with the approved brand, and trademark misuse. See FDA-GLP1-Warning-Letters-Sep-2025.
  • 2024-2025 DOJ wave: Tailor Made Compounding pleads guilty (owner: probation + home detention + ~$1.79M forfeiture); All American Peptide operators and BioPeptide Labs charged. See DOJ-Peptide-Criminal-Prosecutions-2025.
  • 2025-2026 state actions: Ohio Board of Pharmacy consent orders; California AB-1887 disclosure law (effective Jan 1, 2025); Florida clinic-license suspensions. See State-Level-Peptide-Enforcement-2025-2026.

2026 — Vendor closures, more letters, and a partial thaw on research peptides

  • Jan 2026: Science-Bio shuts down — an early grey-market casualty. See Science-Bio-Shutdown-January-2026.
  • Feb 20, 2026: FDA sends 30 warning letters to telehealth firms over compounded-GLP-1 website claims (Pharmaceutical Commerce; Fierce Pharma). See FDA-Telehealth-GLP1-Warning-Letters-Mar-2026.
  • Feb 27, 2026: HHS signals a potential reclassification/loosening of restrictions on research peptides (FDA-Reclassification-Announcement-Feb-2026) — a proposed reversal, not a final rule, and it has not stopped enforcement.
  • Mar 2026: Peptide-Sciences (~$7M/mo) shuts down with no public warning letter — timing aligns with the crackdown. See Peptide-Sciences-Shutdown-March-2026.
  • Mar 31 / Apr 7, 2026: FDA warning letters to 7 peptide companies — including Prime-Sciences, Gram-Peptides, and Mile-High-Compounds — newly treating bacteriostatic water sold alongside peptides as drug distribution. See FDA-Warning-Letters-April-2026.
  • Mid-April 2026: FDA removes ~12 peptides from Category 2 (BPC-157, TB-500, Semax, Epitalon, MOTS-c, Melanotan II, GHK-Cu, KPV, DSIP, Dihexa, Selank, certain Ipamorelin salt forms) (Newtropin summary; secondary sources date this Apr 15 vs Apr 22, 2026 — treat as mid-April pending the Federal Register notice).
    • Critical caveat (do not overstate): removal from Category 2 is not authorization to compound. The peptides enter a transitional state; they must clear PCAC review and formal notice-and-comment rulemaking to land on the 503A bulks list before legal compounding resumes (Newtropin; FDA 503A bulks-list process page). “Not banned” ≠ “approved.”
  • May 1, 2026: FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (“no clinical need”), comment window open to June 29, 2026 — a move to permanently close compounded GLP-1s (Federal Register, 2026-05-01; FDA press). Proposed, not final.
  • Jul 23-24, 2026 (scheduled): PCAC meets to evaluate BPC-157, KPV, TB-500, and MOTS-c (Jul 23) and DSIP/Emideltide, Semax, and Epitalon (Jul 24) for the 503A bulks list (FDA advisory-committee calendar).

Current state (as of June 2026)

  • Compounded GLP-1s: effectively dead. Shortage resolved, discretion ended, OFA injunctions denied, and the FDA is moving to bar them from the 503B list (proposal pending, comments to Jun 29, 2026).
  • Research peptides (BPC-157 et al.): still unapproved drugs. ~12 were lifted out of Category 2 in mid-April 2026, but none are yet on the 503A bulks list — PCAC review is the July 2026 gate. The reclassification is a thaw, not a green light.
  • Enforcement posture: mass warning letters are now routine (55+ in Sep 2025, 30 in Feb 2026, 7 in Apr 2026), the FDA is expanding theories of liability (e.g., bacteriostatic water as a drug), and DOJ criminal referrals are live. Enforcement and reclassification proceed on parallel, independent tracks — being removed from Category 2 does not shield a vendor from current enforcement.

What it means

For vendors

  • Selling GLP-1 compounds is no longer defensible on shortage grounds. Expect letters → injunctions → seizures → criminal referral as the escalation ladder.
  • “Research use only / not for human consumption” disclaimers do not immunize you: the FDA applies the Intended Use Doctrine based on marketing context (dosing tips, before/after photos, human-use framing). See the disclaimer analysis in DOJ-Peptide-Criminal-Prosecutions-2025.
  • Even a clean operator can be hit on ancillary products — the Apr 2026 letters treated bacteriostatic water bundled with peptides as drug distribution (FDA-Warning-Letters-April-2026).
  • The largest vendors are exiting pre-emptively (Peptide-Sciences, Science-Bio) rather than litigate — supply is consolidating and narrowing.

For buyers / researchers

  • Access to compounded GLP-1s via telehealth has largely closed; remaining sources are grey-market and legally exposed.
  • Research-peptide supply is thinning and quality is uncertain — USADA’s chief science officer warns buyers “don’t even know what’s inside that bottle” (USADA).
  • The mid-2026 reclassification does not make BPC-157 a legal therapeutic; it remains an unapproved drug pending PCAC/rulemaking.

For VialBase content strategy

  • This is the central regulatory narrative for the affiliate/GEO site: it explains why vendors close, why “research use only” is the standard framing, and why compounding-vs-grey-market is the key buyer distinction. Tie vendor-status notes back here.
  • regulatory-status-refresh-2026-06 — compound-specific status table (June 2026); corrects the 12-peptide list and GHK-Cu status in this note’s April 2026 timeline entry
  • regulatory-timeline-2024-2026 — full chronology
  • FDA-503A-Category-System — the compounding framework (503A vs 503B, Categories 1/2/3)
  • FDA-Category-2-Designations-2023-2024 — the original peptide restrictions being enforced
  • FDA-Revised-Interim-Policy-Jan-2025 — end of the category-nomination pipeline
  • Semaglutide-Compounding-Shortage-Resolution — the GLP-1 shortage sunset
  • GLP1-Manufacturer-Litigation-2025 — Lilly/Novo + OFA litigation
  • FDA-GLP1-Warning-Letters-Sep-2025 — the 55+ letter wave
  • FDA-Telehealth-GLP1-Warning-Letters-Mar-2026 — the 30-letter telehealth wave
  • FDA-Warning-Letters-April-2026 — the 7-company peptide letters
  • Amino-Asylum-FDA-Raid-Jun-2025 — physical enforcement
  • DOJ-Peptide-Criminal-Prosecutions-2025 — criminal track
  • State-Level-Peptide-Enforcement-2025-2026 — state boards/AGs
  • FDA-Reclassification-Announcement-Feb-2026 — proposed reversal (not final)
  • Science-Bio-Shutdown-January-2026, Peptide-Sciences-Shutdown-March-2026 — vendor closures
  • EMA-Synthetic-Peptide-Guideline-2026, TGA-Australia-Import-Restrictions-2026 — international parallels

Sources

Source: FDA, DOJ, HHS, state boards →